| Document Date: 2008-12-10 01:08:07
Open Document File Size: 29,17 KBShare Result on Facebook
City Osaka / Deerfield / / Company Fujisawa Healthcare Inc. / Gilead Sciences Inc. / Astellas Pharma Inc. / Yamanouchi Pharmaceutical Co. Ltd. / Fujisawa Pharmaceutical Co. Ltd. / / Continent Africa / Asia / North America / Europe / South America / / Country Japan / United States / Canada / / Event M&A / FDA Phase / / IndustryTerm antifungal product / pharmaceutical manufacturer / pharmaceutical products / / MedicalCondition esophageal candidiasis / anaphylaxis / invasive candidiasis / hypersensitivity / pruritus / candida infection / serious diseases / hemolytic anemia / thrombophlebitis / shock / hematologic malignancies / Candida infections / phlebitis / serious hypersensitivity / infection / candida fungal infections / rash / / MedicalTreatment bone marrow transplant / / MusicAlbum Africa / South America / / Organization U.S. Food and Drug Administration / FDA / / Person Ira D. Lawrence / Hideo Fukumoto / Maribeth Landwehr / / / Position Chairman and Chief Executive Officer / Senior Vice President / Research and Development / / Product fluconazole / AmBisome / amphotericin B / Mycamine / Mycamine™ / Echinocandin / / ProvinceOrState Illinois / / Technology transplantation / pharmaceutical products / / URL www.astellas.com / www.fujisawa.com / http /
SocialTag |
Fujisawa Healthcare, Inc. Corporate Communications Three Parkway North Deerfield, Illinois[removed]Tel[removed]Telefax[removed]www.fujisawa.com